- Home
- MVO vs MGX Comparison
MVO vs MGX Comparison
Compare MVO & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVO
- MGX
- Stock Information
- Founded
- MVO 2006
- MGX 2018
- Country
- MVO United States
- MGX United States
- Employees
- MVO N/A
- MGX N/A
- Industry
- MVO Oil & Gas Production
- MGX
- Sector
- MVO Energy
- MGX
- Exchange
- MVO Nasdaq
- MGX NYSE
- Market Cap
- MVO 67.5M
- MGX 65.0M
- IPO Year
- MVO N/A
- MGX 2024
- Fundamental
- Price
- MVO $5.79
- MGX $1.70
- Analyst Decision
- MVO
- MGX Strong Buy
- Analyst Count
- MVO 0
- MGX 4
- Target Price
- MVO N/A
- MGX $13.00
- AVG Volume (30 Days)
- MVO 55.1K
- MGX 297.1K
- Earning Date
- MVO 01-01-0001
- MGX 05-13-2025
- Dividend Yield
- MVO 17.46%
- MGX N/A
- EPS Growth
- MVO N/A
- MGX N/A
- EPS
- MVO 1.46
- MGX N/A
- Revenue
- MVO N/A
- MGX $45,263,000.00
- Revenue This Year
- MVO N/A
- MGX N/A
- Revenue Next Year
- MVO N/A
- MGX $8.34
- P/E Ratio
- MVO $7.29
- MGX N/A
- Revenue Growth
- MVO N/A
- MGX N/A
- 52 Week Low
- MVO $8.85
- MGX $1.23
- 52 Week High
- MVO $13.95
- MGX $6.90
- Technical
- Relative Strength Index (RSI)
- MVO 49.13
- MGX 53.69
- Support Level
- MVO $5.65
- MGX $1.59
- Resistance Level
- MVO $6.00
- MGX $1.82
- Average True Range (ATR)
- MVO 0.16
- MGX 0.11
- MACD
- MVO -0.01
- MGX 0.02
- Stochastic Oscillator
- MVO 35.90
- MGX 70.89
About MVO MV Oil Trust Units of Beneficial Interests
MV Oil Trust is a statutory trust. Its underlying properties consist of MV Partners, LLC's (MV Partners) net interests in all of its oil and natural gas properties, which are located in the Mid-Continent region in the States of Kansas and Colorado. These properties include producing oil and gas wells.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.